Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–14. https://doi.org/10.1016/S0140-6736(18)30010-2.
Article
PubMed
Google Scholar
Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–38. https://doi.org/10.1055/s-2007-1007122.
Article
CAS
PubMed
Google Scholar
Kudo M, Arizumi T, Ueshima K, Sakurai T, Kitano M, Nishida N. Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: proposal of modified Bolondi's subclassification (Kinki criteria). Dig Dis. 2015;33(6):751–8. https://doi.org/10.1159/000439290.
Article
PubMed
Google Scholar
Golfieri R, Bargellini I, Spreafico C, Trevisani F. Patients with Barcelona clinic liver Cancer stages B and C hepatocellular carcinoma: time for a subclassification. Liver Cancer. 2019;8(2):78–91. https://doi.org/10.1159/000489791.
Article
CAS
PubMed
Google Scholar
Wang YY, Zhong JH, Xu HF, Xu G, Wang LJ, Xu D, et al. A modified staging of early and intermediate hepatocellular carcinoma based on single tumour >7 cm and multiple tumours beyond up-to-seven criteria. Aliment Pharmacol Ther. 2019;49(2):202–10. https://doi.org/10.1111/apt.15074.
Article
PubMed
Google Scholar
Rhim H, Lim H K. Radiofrequency ablation of hepatocellular carcinoma: Pros and cons. Gut Liver, 2010. 4 Suppl 1: S113–18.
Seo YS, Kim MS, Yoo HJ, Jang WI, Paik EK, Han CJ, et al. Radiofrequency ablation versus stereotactic body radiotherapy for small hepatocellular carcinoma: a Markov model-based analysis. Cancer Med. 2016;5(11):3094–101. https://doi.org/10.1002/cam4.893.
Article
PubMed
PubMed Central
Google Scholar
Hyun D, Cho SK, Shin SW, Park KB, Lee SY, Park HS, et al. Combined transarterial chemoembolization and radiofrequency ablation for small treatment-naive hepatocellular carcinoma infeasible for ultrasound-guided radiofrequency ablation: long-term outcomes. Acta Radiol. 2018;59(7):773–81. https://doi.org/10.1177/0284185117735349.
Article
PubMed
Google Scholar
Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases. Hepatology. 2018;68(2):723–50. https://doi.org/10.1002/hep.29913.
Article
PubMed
Google Scholar
Macia IGM. Radiobiology of stereotactic body radiation therapy (SBRT). Rep Pract Oncol Radiother. 2017;22(2):86–95. https://doi.org/10.1016/j.rpor.2017.02.010.
Article
Google Scholar
Clinical Practice Guidelines EASL. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. https://doi.org/10.1016/j.jhep.2018.03.019.
Article
Google Scholar
Kim N, Cheng J, Jung I, Liang JD, Shih YL, Huang WY, et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J Hepatol. 2020;73(1):121–9. https://doi.org/10.1016/j.jhep.2020.03.005.
Article
CAS
PubMed
Google Scholar
Moore A, Cohen-Naftaly M, Tobar A, Kundel Y, Benjaminov O, Braun M, et al. Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable hepatocellular carcinoma. Radiat Oncol. 2017;12(1):163. https://doi.org/10.1186/s13014-017-0899-4.
Article
CAS
PubMed
PubMed Central
Google Scholar
Eriguchi T, Tsukamoto N, Kuroiwa N, et al. Repeated stereotactic body radiation therapy for hepatocellular carcinoma. Practical Radiation Oncology, 2020(Online ahead of print).
Loi M, Comito T, Franzese C, et al. Stereotactic body radiotherapy in hepatocellular carcinoma: Patient selection and predictors of outcome and toxicity. J Cancer Res Clin Oncol, 2020(Online ahead of print).
Tsurugai Y, Takeda A, Eriguchi T, et al. Hypofractionated radiotherapy for hepatocellular carcinomas adjacent to the gastrointestinal tract. Hepatol Res, 2020(Online ahead of print).
Baumann BC, Wei J, Plastaras JP, Lukens JN, Damjanov N, Hoteit M, et al. Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma: high rates of local control with low toxicity. Am J Clin Oncol. 2018;41(11):1118–24. https://doi.org/10.1097/COC.0000000000000435.
Article
PubMed
Google Scholar
Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, et al. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepatocellular carcinoma. J Clin Oncol. 2016;34(5):452–9. https://doi.org/10.1200/JCO.2015.61.4925.
Article
CAS
PubMed
Google Scholar
Hara K, Takeda A, Tsurugai Y, Saigusa Y, Sanuki N, Eriguchi T, et al. Radiotherapy for hepatocellular carcinoma results in comparable survival to radiofrequency ablation: a propensity score analysis. Hepatology. 2019;69(6):2533–45. https://doi.org/10.1002/hep.30591.
Article
PubMed
Google Scholar
Lee J, Shin IS, Yoon WS, Koom WS, Rim CH. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review. Radiother Oncol. 2020;145:63–70. https://doi.org/10.1016/j.radonc.2019.12.004.
Article
PubMed
Google Scholar
Fu Y, Xi M, Pan Y, Chen J, Wang J, Liu S, et al. Stereotactic body radiotherapy as a salvage therapy after incomplete radiofrequency ablation for hepatocellular carcinoma: a retrospective cohort study. J Oncol. 2020;2020:4835653–9. https://doi.org/10.1155/2020/4835653.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pollom EL, Lee K, Durkee BY, Grade M, Mokhtari DA, Wahl DR, et al. Cost-effectiveness of stereotactic body radiation therapy versus radiofrequency ablation for hepatocellular carcinoma: a Markov modeling study. Radiology. 2017;283(2):460–8. https://doi.org/10.1148/radiol.2016161509.
Article
PubMed
Google Scholar
Pan YX, Xi M, Fu YZ, Hu DD, Wang JC, Liu SL, et al. Stereotactic body radiotherapy as a salvage therapy after incomplete radiofrequency ablation for hepatocellular carcinoma: a retrospective propensity score matching study. Cancers (Basel). 2019;11(8):1116. https://doi.org/10.3390/cancers11081116.
Article
CAS
Google Scholar
Kudo M, Matsui O, Izumi N, Iijima H., Kadoya M., Imai Y., Okusaka T., Miyayama S., Tsuchiya K., Ueshima K., Hiraoka A., Ikeda M., Ogasawara S., Yamashita T., Minami T., Yamakado K., Liver Cancer Study Group of Japan. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan. Liver Cancer, 2014. 3(3–4): 458–468, DOI: https://doi.org/10.1159/000343875.
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60. https://doi.org/10.1055/s-0030-1247132.
Article
CAS
PubMed
Google Scholar
Wang F, Numata K, Nihonmatsu H, Chuma M, Moriya S, Nozaki A, et al. Intraprocedurally EOB-MRI/US fusion imaging focusing on hepatobiliary phase findings can help to reduce the recurrence of hepatocellular carcinoma after radiofrequency ablation. Int J Hyperth. 2020;37(1):1149–58. https://doi.org/10.1080/02656736.2020.1825837.
Article
CAS
Google Scholar
Hao Y, Numata K, Ishii T, Fukuda H, Maeda S, Nakano M, et al. Rate of local tumor progression following radiofrequency ablation of pathologically early hepatocellular carcinoma. World J Gastroenterol. 2017;23(17):3111–21. https://doi.org/10.3748/wjg.v23.i17.3111.
Article
PubMed
PubMed Central
Google Scholar
Takeda A, Sanuki N, Tsurugai Y, Iwabuchi S, Matsunaga K, Ebinuma H, et al. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer. 2016;122(13):2041–9. https://doi.org/10.1002/cncr.30008.
Article
PubMed
Google Scholar
Zeng ZC, Seong J, Yoon SM, Cheng JCH, Lam KO, Lee AS, et al. Consensus on stereotactic body radiation therapy for small-sized hepatocellular carcinoma at the 7th Asia-Pacific primary liver Cancer expert meeting. Liver Cancer. 2017;6(4):264–74. https://doi.org/10.1159/000475768.
Article
PubMed
PubMed Central
Google Scholar
Llovet JM, Lencioni R. MRECIST for HCC: performance and novel refinements. J Hepatol. 2020;72(2):288–306. https://doi.org/10.1016/j.jhep.2019.09.026.
Article
PubMed
Google Scholar
Kunzli BM, Abitabile P, Maurer CA. Radiofrequency ablation of liver tumors: actual limitations and potential solutions in the future. World J Hepatol. 2011;3(1):8–14. https://doi.org/10.4254/wjh.v3.i1.8.
Article
PubMed
PubMed Central
Google Scholar
Yoon JH, Lee JM, Klotz E, Woo H, Yu MH, Joo I, et al. Prediction of local tumor progression after radiofrequency ablation (RFA) of hepatocellular carcinoma by assessment of ablative margin using pre-RFA MRI and post-RFA CT registration. Korean J Radiol. 2018;19(6):1053–65. https://doi.org/10.3348/kjr.2018.19.6.1053.
Article
PubMed
PubMed Central
Google Scholar
Yip C, Hennedige TP, Cook GJ, et al. Imaging assessment after SBRT for hepatocellular carcinoma. Hepatoma Research. 2020;6(44):1–08. https://doi.org/10.20517/2394-5079.2020.30.
Article
CAS
Google Scholar
Tetreau R, Llacer C, Riou O, et al. Evaluation of response after SBRT for liver tumors. Rep Pract Oncol Radiother. 2017;22(2):170–5. https://doi.org/10.1016/j.rpor.2015.12.004.
Article
PubMed
Google Scholar
Mendiratta-Lala M, Masch W, Shankar PR, Hartman HE, Davenport MS, Schipper MJ, et al. Magnetic resonance imaging evaluation of hepatocellular carcinoma treated with stereotactic body radiation therapy: long term imaging follow-up. Int J Radiat Oncol Biol Phys. 2019;103(1):169–79. https://doi.org/10.1016/j.ijrobp.2018.09.004.
Article
PubMed
Google Scholar
Zhao Z, Wu J, Liu X, Liang M, Zhou X, Ouyang S, et al. Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy. Cancer Lett. 2018;421:73–81. https://doi.org/10.1016/j.canlet.2018.02.024.
Article
CAS
PubMed
Google Scholar
Zhang N, Li H, Qin C, Ma D, Zhao Y, Zhu W, et al. Insufficient radiofrequency ablation promotes the metastasis of residual hepatocellular carcinoma cells via upregulating flotillin proteins. J Cancer Res Clin Oncol. 2019;145(4):895–907. https://doi.org/10.1007/s00432-019-02852-z.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kang TW, Lim HK, Cha DI. Aggressive tumor recurrence after radiofrequency ablation for hepatocellular carcinoma. Clin Mol Hepatol. 2017;23(1):95–101. https://doi.org/10.3350/cmh.2017.0006.
Article
PubMed
PubMed Central
Google Scholar
Kang TW, Kim JM, Rhim H, Lee MW, Kim YS, Lim HK, et al. Small hepatocellular carcinoma: radiofrequency ablation versus nonanatomic resection--propensity score analyses of long-term outcomes. Radiology. 2015;275(3):908–19. https://doi.org/10.1148/radiol.15141483.
Article
PubMed
Google Scholar
Brillet PY, Paradis V, Brancatelli G, Rangheard AS, Consigny Y, Plessier A, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma before liver transplantation: a prospective study with histopathologic comparison. AJR Am J Roentgenol. 2006;186(5 Suppl):S296–305. https://doi.org/10.2214/AJR.04.1927.
Article
PubMed
Google Scholar
Cassinotto C, Aube C, Dohan A. Diagnosis of hepatocellular carcinoma: an update on international guidelines. Diagn Interv Imaging. 2017;98(5):379–91. https://doi.org/10.1016/j.diii.2017.01.014.
Article
CAS
PubMed
Google Scholar